501 related articles for article (PubMed ID: 16468468)
21. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
22. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
23. Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age.
Verma S; Jackisch C
Expert Rev Anticancer Ther; 2011 Feb; 11(2):277-86. PubMed ID: 21342045
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
25. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
26. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
27. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
28. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
[TBL] [Abstract][Full Text] [Related]
29. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N; Paridaens R; Cufer T
Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
[TBL] [Abstract][Full Text] [Related]
30. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
31. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
Winer E
Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
[No Abstract] [Full Text] [Related]
32. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
Goss PE
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Ryan PD; Goss PE
Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
[TBL] [Abstract][Full Text] [Related]
34. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
35. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
36. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
Smith IE; Arnedos M
Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
[TBL] [Abstract][Full Text] [Related]
37. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
38. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
39. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
40. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
Jonat W
MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
